Inpharma 1331 - 30 Mar 2002 Antichlamydial therapy after MI improves survival Exposure to antichlamydial therapy within the first 3 months following a myocardial infarction (MI) appears to confer a small survival benefit, according to researchers from Canada. They conducted a retrospective review of 26 195 patients with an MI, comparing patients exposed to antibacterials with antichlamydial activity (tetracyclines, macrolides, quinolones), those exposed to sulfa drugs to which Chlamydia pneumoniae is not susceptible and those not given either type of antibacterial. Separate analyses were done for patients exposed within the first 3 months after an MI and those exposed during the 6 months preceding an MI. For individuals exposed within the first 3 months after an MI, the 1-year mortality rate was similar across the 3 treatment groups, but the 2-year mortality data favoured the antichlamydial therapy group (15.9 vs 23 and 20%). In an adjusted survival analysis, the risk of death was slightly higher in those who received sulfa drugs (relative risk 1.38; 95% CI 1.04–1.82) and those who did not receive antichlamydial or sulfa antibacterials (1.29; 1.05–1.59), compared with the antichlamydial therapy group. However, exposure to antichlamydial antibacterials during the 6 months before an MI did not affect survival. The researchers comment that the findings of this study warrant further, prospective studies to evaluate C. pneumoniae eradication in the prevention and treatment of acute coronary artery syndromes. Pilote L, et al. Antibiotics against Chlamydia pneumoniae and prognosis after acute myocardial infarction. American Heart Journal 143: 294-300, Feb 2002 800900426 1 Inpharma 30 Mar 2002 No. 1331 1173-8324/10/1331-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Antichlamydial therapy after MI improves survival

Download PDF Report

View
220
Download
1

Embed Size (px)

Citation preview

Inpharma 1331 - 30 Mar 2002

Antichlamydial therapy after MIimproves survival

Exposure to antichlamydial therapy within the first 3months following a myocardial infarction (MI) appearsto confer a small survival benefit, according toresearchers from Canada.

They conducted a retrospective review of 26 195patients with an MI, comparing patients exposed toantibacterials with antichlamydial activity (tetracyclines,macrolides, quinolones), those exposed to sulfa drugs towhich Chlamydia pneumoniae is not susceptible andthose not given either type of antibacterial. Separateanalyses were done for patients exposed within the first3 months after an MI and those exposed during the 6months preceding an MI.

For individuals exposed within the first 3 months afteran MI, the 1-year mortality rate was similar across the 3treatment groups, but the 2-year mortality data favouredthe antichlamydial therapy group (15.9 vs 23 and 20%).In an adjusted survival analysis, the risk of death wasslightly higher in those who received sulfa drugs(relative risk 1.38; 95% CI 1.04–1.82) and those who didnot receive antichlamydial or sulfa antibacterials (1.29;1.05–1.59), compared with the antichlamydial therapygroup.

However, exposure to antichlamydial antibacterialsduring the 6 months before an MI did not affect survival.

The researchers comment that the findings of thisstudy warrant further, prospective studies to evaluate C.pneumoniae eradication in the prevention andtreatment of acute coronary artery syndromes.Pilote L, et al. Antibiotics against Chlamydia pneumoniae and prognosis afteracute myocardial infarction. American Heart Journal 143: 294-300, Feb2002 800900426